OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

  title={OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.},
  author={Michael J Gough and Carl E. Ruby and William L Redmond and Birat Dhungel and Alexis Brown and Andrew D. Weinberg},
  journal={Cancer research},
  volume={68 13},
Acquisition of full T-cell effector function and memory differentiation requires appropriate costimulatory signals, including ligation of the costimulatory molecule OX40 (TNFRSF4, CD134). Tumors often grow despite the presence of tumor-specific T cells and establish an environment with weak costimulation and immune suppression. Administration of OX40 agonists has been shown to significantly increase the survival of tumor-bearing mice and was dependent on the presence of both CD4 and CD8 T cells… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 64 extracted citations

New Immunotherapy Strategies in Breast Cancer

International journal of environmental research and public health • 2017
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 54 references

Gr-1+CD115+ immature myeloid suppressor cells mediate the development of Research

B Huang, PY Pan, Q Li
on May • 2008
View 9 Excerpts
Highly Influenced

tumor - induced T regulatory cells and T - cell anergy in tumorbearing host

Q Zhang, X Yang, M Pins

Repeated epicutaneous exposures to ovalbumin progressively induce atopic dermatitis-like skin lesions in mice.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology • 2007
View 2 Excerpts

Similar Papers

Loading similar papers…